论文部分内容阅读
目的探讨小剂量尿激酶联合胞磷胆碱钠治疗脑干梗死的疗效。方法选取2010年1月—2013年6月于乐亭县中医医院神经内科住院的急性脑干梗死患者30例,结合患者及家属意愿将患者分为治疗组与对照组,各15例。治疗组予以尿激酶联合胞磷胆碱钠治疗治疗,对照组予以奥扎格雷钠治疗。观察两组患者脑卒中临床神经功能缺损程度评分(NIHSS)、临床疗效及不良反应发生情况。结果治疗前两组患者NIHSS评分比较,差异无统计学意义(P>0.05),治疗后24h、14d治疗组患者NIHSS评分低于对照组,差异有统计学意义(P<0.05);治疗组患者总有效率高于对照组(P<0.05);两组患者均未发生严重不良反应。结论小剂量尿激酶联合胞磷胆碱钠治疗脑干梗死的疗效显著,可改善患者预后,且不良反应小。
Objective To investigate the efficacy of low-dose urokinase combined with citicoline sodium in the treatment of cerebral infarction. Methods Thirty patients with acute brainstem infarction hospitalized in the Department of Neurology, Laoting Hospital of Traditional Chinese Medicine from January 2010 to June 2013 were selected. The patients were divided into treatment group and control group according to the wishes of patients and their families, 15 cases each. The treatment group was treated with urokinase combined with citicoline sodium and the control group with ozagrel sodium. The clinical neurological deficit scores (NIHSS), clinical efficacy and adverse reactions in the two groups were observed. Results There was no significant difference in the NIHSS score between the two groups before treatment (P> 0.05). NIHSS scores of the treatment group at 24 and 14 days after treatment were lower than those of the control group (P <0.05) The total effective rate was higher than that of the control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Low-dose urokinase combined with citicoline sodium treatment of brain stem infarction significant effect, can improve the prognosis of patients with little adverse reactions.